A Phase 4 interventional study of Pitavastatin (NK-104) and Diltiazem (Cardizem LA) 240 mg QD in Healthy, sponsored by Kowa Research Institute, Inc.. Completed at 1 site in United States. Open to participants aged 18 Years to 45 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2012-07-13.
Sponsored by Kowa Research Institute, Inc. (part of Kowa Company, Ltd.) · Phase 4 and Interventional
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
This is a Phase 4, single-center, open-label, fixed-sequence, multiple-dose, 2-way drug-drug interaction study.
Each subject will qualify for entry into the study not more than 30 days prior to admission into the clinical unit. Subjects will check into the clinical unit on Day -1 for baseline assessments. During the treatment period, each subject will receive a once-daily dose of pitavastatin 4 mg on Days 1 through 5 and on Days 11 through 15 and a once-daily dose of diltiazem 240 mg on Days 6 through 15. Subjects will fast overnight for at least 8 hours before dosing and will remain fasted until 4 hours after dosing on the morning of Days 5, 10, and 15.
Kowa Research Institute, Inc. is the lead sponsor of 47 studies on the registry; 1 is open to participants now.
Of its 20 completed or terminated interventional studies of FDA-regulated products, 9 (45%) have results posted.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
There was 1 treatment period, with each subject receiving a once-daily dose of pitavastatin 4 mg on Days 1 through 5 and on Days 11 through 15 and a once-daily dose of diltiazem 240 mg on Days 6 through 15
Drug: Pitavastatin (NK-104) · Drug: Diltiazem (Cardizem LA) 240 mg QD
pitavastatin (NK-104) 4 mg once daily (QD)
Also known as: Livalo
Diltiazem (Cardizem LA) 240 mg QD
NK-104 AUC
Time frame: 15 Days
Number of Participants With at Least One Adverse Event.
Time frame: 24 Days
1st Subject Enrolled 05 May 2011, Last Subject Completed 12 July 2011 at PPD Inc. 7551 Metro Center Drive Suite 200 Austin, TX 78744
| Milestone | All Subjects |
|---|---|
| Started | 28 |
| Completed | 28 |
| Not completed | 0 |
| Milestone | All Subjects |
|---|---|
| Started | 28 |
| Completed | 28 |
| Not completed | 0 |
| Milestone | All Subjects |
|---|---|
| Started | 28 |
| Completed | 27 |
| Not completed | 1 |
| Withdrew: Personal reasons | 1 |
| ng * h/mL | All Subjects |
|---|---|
| NK-104 AUC | 208.92 ± 86.54 |
| Participants | All Subjects |
|---|---|
| Number of Participants With at Least One Adverse Event. | 12 |
Non-serious events are listed at a 4% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| All Subjects | — | 0/28 (0%) | 12/28 (42.9%) |
| Event | All Subjects |
|---|---|
| HeadacheNervous system disorders | 5/28 |
| PresyncopeNervous system disorders | 3/28 |
| NasopharyngitisInfections and infestations | 2/28 |
| CoughRespiratory, thoracic and mediastinal disorders | 2/28 |
| Age, Categorical(Participants) | All Subjects |
|---|---|
| <=18 years | 0 |
| Between 18 and 65 years | 28 |
| >=65 years | 0 |
| Age Continuous(years) | All Subjects |
|---|---|
| Mean | 29.2 ± 7.63 |
| Sex: Female, Male(Participants) | All Subjects |
|---|---|
| Female | 11 |
| Male | 17 |
| Region of Enrollment(participants) | All Subjects |
|---|---|
| United States | 28 |
The record gives a start of May 2011, a primary completion of Jun 2011 and a completion of Jul 2011. It does not say whether these dates are actual or estimated.
Results were first posted in Apr 2012, 10 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jul 2012. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Pitavastatin · Diltiazem
Kowa Research Institute, Inc. →